Diagnostic value of HMGAs, p53 and β-catenin in discriminating adenocarcinoma from adenoma or reactive atypia in ampulla and common bile duct biopsies

Histopathology

Volumn 62, Issue 5, 2013, Pages 778-787

  Zakharov, Vladislav ^a   Ren, Bing ^a   Ryan, Charlotte ^a   Cao, Wenqing ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Ampulla; Biopsy; Common bile duct; HMGA1; HMGA2

Indexed keywords

BETA CATENIN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; NUCLEAR PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT BIOPSY; CANCER PROGNOSIS; CLINICAL ARTICLE; COMMON BILE DUCT; COMMON BILE DUCT BIOPSY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; STAINING; TISSUE SECTION; TUMOR VOLUME; VATER PAPILLA;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; BETA CATENIN; CHOLANGITIS; COMMON BILE DUCT NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HMGA PROTEINS; HUMANS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875587100     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12084     Document Type: Article

References (50)

1. Kim YS, Kim HG, Han J et al. The significance of p53 and K-ras immunocytochemical staining in the diagnosis of malignant biliary obstruction by brush cytology during ERCP. Gut Liver 2010; 4; 219-225.
2. Schmidt MT, Himmelfarb EA, Shafi H, Lin F, Xu H, Wang HL. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 478-487.
3. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum. Pathol. 2010; 41; 1210-1219.
4. Ligato S, Zhao H, Mandich D, Cartun RW. KOC (K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies. Diagn. Cytopathol. 2008; 36; 561-567.
5. Tretiakova M, Antic T, Westerhoff M et al. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions. Am. J. Surg. Pathol. 2012; 36; 101-108.
6. Barr Fritcher EG, Kipp BR, Slezak JM et al. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am. J. Clin. Pathol. 2007; 128; 272-279.
7. Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 1990; 265; 8573-8582.
8. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001; 277; 63-81.
9. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315; 1576-1579.
10. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin. Cancer Res. 2008; 14; 2334-2340.
11. Chiappetta G, Avantaggiato V, Visconti R et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996; 13; 2439-2446.
12. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995; 376; 771-774.
13. Sgarra R, Rustighi A, Tessari MA et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004; 574; 1-8.
14. Resar LM. The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res. 2010; 70; 436-439.
15. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007; 7; 899-910.
16. Abe N, Watanabe T, Suzuki Y et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br. J. Cancer 2003; 89; 2104-2109.
17. Chen X, Lechago J, Ertan A et al. Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia. Cancer Epidemiol. Biomarkers Prev. 2004; 13; 30-33.
18. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 2006; 66; 11613-11622.
19. Liau SS, Jazag A, Ito K, Whang EE. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Br. J. Cancer 2007; 96; 993-1000.
20. Liau SS, Rocha F, Matros E, Redston M, Whang E. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008; 113; 302-314.
21. Hristov AC, Cope L, Reyes MD et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod. Pathol. 2009; 22; 43-49.
22. Hristov AC, Cope L, Di Cello F et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod. Pathol. 2010; 23; 98-104.
23. Piscuoglio S, Zlobec I, Pallante P et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology 2012; 60; 397-404.
24. Lowy AM, Knight J, Groden J. Restoration of E-cadherin/beta-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. Surgery 2002; 132; 141-148.
25. Norfadzilah MY, Pailoor J, Retneswari M, Chinna K, Noor LM. P53 expression in invasive pancreatic adenocarcinoma and precursor lesions. Malays. J. Pathol. 2011; 33; 89-94.
26. DiGiuseppe JA, Hruban RH, Goodman SN et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. 1994; 101; 684-688.
27. Zhang SY, Ruggeri B, Agarwal P et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch. Pathol. Lab. Med. 1994; 118; 150-154.
28. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996; 53; 104-111.
29. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am. J. Pathol. 1993; 142; 1534-1543.
30. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 2007; 17; 45-51.
31. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005; 19; 877-890.
32. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007; 19; 150-158.
33. Wang X, Goode EL, Fredericksen ZS et al. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2008; 17; 2101-2108.
34. Kastritis E, Murray S, Kyriakou F et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int. J. Cancer 2009; 124; 103-108.
35. Arber N, Hibshoosh H, Yasui W et al. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epidemiol. Biomarkers Prev. 1999; 8; 1101-1105.
36. Heiser PW, Cano DA, Landsman L et al. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 2008; 135; 1288-1300.
37. Cates JM, Black J, Wolfe CC et al. Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy. Hum. Pathol. 2012; 43; 1418-1424.
38. Furic L, Rong L, Larsson O et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl Acad. Sci. USA 2010; 107; 14134-14139.
39. Pancreatic Section of the British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, Royal College of Pathologists, Special Interest Group for Gastro-Intestinal Radiology. Guidelines for the management of patients with pancreatic cancer: periampullary and ampullary carcinomas. Gut 2005; 54(Suppl. 5); v1-v16.
40. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology 1995; 22; 774-779.
41. Younes M, Riley S, Genta RM, Mosharaf M, Mody DR. p53 protein accumulation in tumors of the ampulla of Vater. Cancer 1995; 76; 1150-1154.
42. Thompson AM, Anderson TJ, Condie A et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int. J. Cancer 1992; 50; 528-532.
43. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52; 4828-4831.
44. Laurent C, Svrcek M, Flejou JF et al. Immunohistochemical expression of CDX2, beta-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer. Inflamm. Bowel Dis. 2011; 17; 232-240.
45. Segal F, Kaspary AP, Prolla JC, Leistner S. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. Cancer Lett. 2004; 210; 213-218.
46. Kolligs FT, Bommer G, Goke B. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 2002; 66; 131-144.
47. Yamazaki K, Hanami K, Nagao T, Asoh A, Sugano I, Ishida Y. Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation. Mol. Pathol. 2003; 56; 336-341.
48. Imai Y, Oda H, Tsurutani N, Nakatsuru Y, Inoue T, Ishikawa T. Frequent somatic mutations of the APC and p53 genes in sporadic ampullary carcinomas. Jpn. J. Cancer Res. 1997; 88; 846-854.
49. Kawakami M, Kimura Y, Furuhata T et al. beta-Catenin alteration in cancer of the ampulla of Vater. J. Exp. Clin. Cancer Res. 2002; 21; 23-27.
50. Hsu HP, Shan YS, Jin YT, Lai MD, Lin PW. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J. Surg. Oncol. 2010; 101; 356-362.